Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Dispatch

Murine Typhus in Canary Islands, Spain, 1999–2015

José María Robaina-Bordón, Cristina Carranza-Rodríguez, Michele Hernández-Cabrera, Margarita Bolaños-Rivero, Elena Pisos-Álamo, Nieves Jaén-Sánchez, Araceli Hernández-Betancor, Laura Suárez-Hormiga, and José Luis Pérez-ArellanoComments to Author 
Author affiliations: Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain (J.M. Robaina-Bordón, C. Carranza-Rodríguez, M. Hernández-Cabrera, E. Pisos-Álamo, N. Jaén-Sánchez, L. Suárez-Hormiga, J.L. Pérez-Arellano); Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria (J.M. Robaina-Bordón); Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria (C. Carranza-Rodríguez, M. Hernández-Cabrera, M. Bolaños-Rivero, E. Pisos-Álamo, N. Jaén-Sánchez, A. Hernández-Betancor, L. Suárez-Hormiga, J.L. Pérez-Arellano)

Main Article

Table 2

Laboratory test results for patients with cases of endemic murine typhus, Canary Islands, Spain, 1999–2015*

Finding No. (%) IgM >1:1,280, no. (%)† 4-fold IgG titer increase, no. (%)‡ p-value Cutoff values
Anemia, n = 220 38 (17.3) 16 (22.5) 22 (14.8) 0.15 <12 g/dL Hb in women, <13 g/dL Hb in men
Leukopenia, n = 220 23 (10.5) 7 (9.9) 16 (10.7) 0.26 <4,000/μL
Leukocytosis, n = 220 42 (19.1) 18 (25.4) 24 (16.1) 0.26 >11,000/μL
Thrombocytopenia, n = 218 127 (58.3) 28 (39.4) 99 (67.3) <0.01 <150,000/μL
Increased ESR, n = 106 64 (60.4) 27 (65.9) 37 (56.9) 0.42 Upper limit of normality calculated according to age and sex
Prolonged PT, n = 197 82 (41.6) 27 (42.9) 55 (41) 0.81 <80%
Increased aPTTr, n = 188 6 (3.2) 2 (3.4) 4 (3.1) 0.99 >1.2
Plasma Cr increase, n = 215 47 (21.9) 16 (23.5) 31 (21.1) 0.72 >1.2 mg/dL
Hyponatremia, n = 205 119 (58) 30 (50) 89 (61.4) 0.13 <135 mEq/L
Plasma CK increase, n = 97 20 (20.6) 5 (13.5) 15 (25) 0.17 >232 U/L
Plasma urea increase, n = 211 36 (17.1) 12 (18.5) 24 (16.4) 0.72 >40 mg/dL
Plasma LDH increase, n = 138 131 (94.9) 40 (90.9) 91 (96.8) 0.21 >190 U/L
Plasma ALT increase, n = 197 184 (93.4) 59 (92.2) 125 (94) 0.76 >35 U/L
Plasma AST increase, n = 196 182 (92.9) 55 (88.7) 127 (94.81) 0.14 >35 U/L
Plasma AP increase, n = 109 38 (34.9) 10 (25.6) 28 (40) 0.15 >136 U/L
Plasma GGT increase, n = 166 91 (54.8) 29 (52.7) 62 (55.9) 0.74 >85 U/L
Microhematuria, n = 195 146 (74.9) 45 (72.6) 101 (75.9) 0.6 >5 RBCs/mm3
Proteinuria, n = 195 169 (86.7) 54 (87.1) 115 (86.5) 0.9 Positive urine test strip
Leukocyturia, n = 194 123 (63.4) 38 (62.3) 85 (63.9) 0.83 >10 WBCs/mm3

*ALT, alanine aminotransferase; AP, alkaline phosphatase; aPTTr, activated partial thromboplastin time ratio; AST, aspartate aminotransferase; Cr, creatinine; CK, creatine kinase; ESR, erythrocyte sedimentation rate; GGT, γ-glutamyl transpeptidase; Hb, hemoglobin; LDH, lactate dehydrogenase; PT, prothrombin Time; RBCs, red blood cells; WBCs, white blood cells.
†Patients given a diagnosis by testing of 1 sample (criterion 1). 
‡Patients given a diagnosis by testing of 2 consecutive samples (criterion 2).

Main Article

Page created: October 13, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external